Introduction: The Paradox of Jacob deGrom

Jacob deGrom’s journey from a late-round draft pick to a two-time Cy Young Award winner is a story of raw dominance and relentless precision. But how did his performance shift when the financial stakes skyrocketed? By comparing his numbers before and after his major contracts, we can separate the myth from the reality and understand whether the pressure—or the security—of a nine-figure deal truly changed the pitcher on the mound. The answer reveals a fascinating paradox: deGrom became even more dominant per inning after signing, yet his body began to betray him at the exact moment he secured generational wealth.

Early Career and Rise to Stardom (2014–2018)

Selected by the New York Mets in the ninth round of the 2010 MLB draft, deGrom debuted in 2014 as a relatively unheralded 26-year-old rookie. He quickly defied expectations, posting a 2.69 ERA and winning the National League Rookie of the Year Award. Over the next four seasons, he established himself as one of the game’s elite arms, using a devastating fastball-slider combination and elite command. His early-career salaries were modest—approximately $500,000 to $600,000 annually through the league’s pre-arbitration structure—yet his performance screamed “ace.”

Key Pre-Contract Metrics (2014–2018)

  • ERA: 2.68 (over 721 innings pitched)
  • Strikeouts per 9 innings (K/9): 9.6
  • Walks per 9 (BB/9): 2.2
  • WHIP: 1.10
  • FIP (Fielding Independent Pitching): 2.62
  • fWAR total: 22.4 (average 4.5 per season)
  • Cy Young finishes: 7th (2015), 8th (2017), 2nd (2018)
  • All-Star selections: 2 (2015, 2018)

His 2018 season was particularly historic. Despite a 10-9 record due to poor run support, deGrom led the NL in ERA (1.70), strikeouts (269), and WHIP (0.91), capturing his first Cy Young Award. At that point, he had outpitched his salary by an enormous margin. His 9.0 bWAR in 2018 was worth roughly $70 million on the open market according to typical valuation models—more than ten times what the Mets paid him that season.

The First Major Contract: 2019 Extension with the Mets

In March 2019, deGrom signed a five-year, $137.5 million contract extension with the Mets, covering 2020–2024. It was, at the time, the largest contract for a right-handed pitcher in baseball history. The deal bought out his final two arbitration years and three free-agent seasons, with an average annual value of $27.5 million. This contract represented a seismic shift in deGrom’s financial reality, but also placed enormous expectations on his shoulders.

Pre-Extension Peak (2018–2019)

In the year immediately before signing, deGrom was untouchable. After inking the deal, he continued to dominate with an even higher strikeout rate. His 2019 season—still technically pre-extension in service time but post-announcement—saw him post a 2.43 ERA and 255 strikeouts in 204 innings, earning him a second Cy Young Award. His K/9 jumped to 11.3, and his WHIP dropped to 0.97. It was the finest sustained pitching the Mets had seen since Tom Seaver.

Post-Extension Performance (2020–2021)

The post-signing period brought both brilliance and fragility. deGrom’s performance reached unprecedented heights, but his workload began to crater.

  • 2020 (shortened season): 2.38 ERA, 104 strikeouts in 68 innings (13.8 K/9)
  • 2021: 1.08 ERA, 146 strikeouts in 92 innings (14.3 K/9) — arguably the most dominant half-season ever by a starting pitcher
  • Injuries: deGrom missed significant time in 2021 due to forearm tightness and a hamstring strain, then missed most of 2022 with a stress reaction in his scapula

From 2020 through the first half of 2021, deGrom’s numbers were off the charts. His 1.08 ERA in 2021 was the lowest by a qualified starter since Bob Gibson’s 1.12 in 1968. Yet the workload shrank dramatically—he pitched just 92 innings in 2021 and 64.1 innings in 2022 before undergoing elbow surgery. The contrast is stark: a pitcher who averaged 190 innings per year from 2014–2019 became a part-time phenom. While his stuff remained elite, his availability collapsed. Baseball Reference shows that his bWAR per 200 innings actually increased post-extension (from 6.5 to 8.0), but his career bWAR accumulation slowed due to lost time.

Advanced Metrics Tell a Story of Escalation

To understand the post-extension surge, we must look beyond ERA. In 2021, deGrom’s fastball averaged 99.0 mph, up from 97.2 mph in 2018. His slider whiff rate climbed to 54%, and his xwOBA (expected weighted on-base average) against was an absurd .199. According to Fangraphs, his 2021 season produced a 4.7 fWAR in just 92 innings—a rate that would have surpassed 10 fWAR over a full season. The money didn’t buy new pitches; it may have bought the freedom to throw with maximum effort on every pitch, which in turn increased injury risk.

The Blockbuster Move: Texas Rangers Contract (2023–Present)

After opting out of his Mets deal in November 2022, deGrom signed a five-year, $185 million contract with the Texas Rangers. The guaranteed money—$185 million with an average of $37 million per year—placed immense expectations on a 34-year-old pitcher coming off Tommy John surgery. The Rangers were betting that deGrom’s dominant innings, even if limited, could propel them to a championship.

Performance Before the Rangers Deal: 2022

In his final season with the Mets, deGrom made only 11 starts, pitching to a 3.08 ERA with 102 strikeouts in 64.1 innings (14.3 K/9). His fastball velocity still averaged 98.8 mph, but the elbow was clearly a ticking time bomb. He underwent a hybrid Tommy John surgery in June 2023, which cost him the remainder of that season and most of 2024.

Performance After the Rangers Deal: 2023–2024

  • 2023: 6 starts, 2.67 ERA, 45 strikeouts in 30.1 innings (13.4 K/9) — then season-ending surgery in June
  • 2024: 3 starts, 0.69 ERA, 14 strikeouts in 13.0 innings before a right elbow strain ended his season in April

The sample sizes are minuscule, but the quality remains elite. When healthy, deGrom has never lost his dominance. Yet his total innings from 2020–2024 (approx. 300) are fewer than many pitchers throw in a single healthy season. The financial commitment from Texas has yet to yield more than a dozen starts combined.

According to Fangraphs, his 2024 Statcast data shows a slider whiff rate of 52.4% and a fastball that still averaged 98.5 mph—confirming his stuff hasn’t declined, only his durability. The ESPN injury timeline documents a cascade of elbow, forearm, shoulder, and side issues that began shortly after his first big payday.

To understand the contract impact, we must look beyond raw numbers and consider availability. Below is a side-by-side comparison of deGrom’s per-162-game averages before and after his first major contract, adjusted for the shortened 2020 season.

Metric Pre-Extension (2014–2018) Post-Extension (2019–2024)1
Innings per season 180 92
ERA 2.68 2.03
FIP 2.62 1.99
K/9 9.6 13.9
BB/9 2.2 1.7
HR/9 0.6 0.5
WHIP 1.10 0.87
fWAR per 200 IP 6.8 8.4
Starts per season 31 16
1 Includes 2020 pro-rated. Source: Baseball-Reference and Fangraphs.

The table reveals a tension: per-inning, deGrom became more dominant after signing—higher strikeouts, lower walks, lower ERA. But his workload dropped by nearly 50 percent. The financial security didn’t make him complacent; instead, it may have allowed him to push even harder, contributing to the injury risk that has defined his post-extension years. His average fastball velocity increased from 97.0 mph pre-extension to 98.8 mph post-extension, and his slider usage rose from 36% to 44%. These changes made him more unhittable but also more fragile.

The Cost of Maximum Effort

Research by Dr. Glenn Fleisig of the American Sports Medicine Institute has shown that pitchers who throw harder are more likely to sustain elbow injuries. deGrom’s velocity increase after signing the Mets extension aligns with this risk profile. Between 2014 and 2018, his average fastball was around 96.5 mph; from 2019 onward, it hovered near 99 mph. The extra 2.5 mph may have been the difference between a Hall-of-Fame career arc and a cautionary tale about the physical toll of elite performance.

External Factors and Context

External factors also play a role. The COVID-shortened 2020 season disrupted training cycles, and the Mets’ handling of deGrom’s injuries in 2021–2022 drew criticism from medical experts. The team’s decision to allow deGrom to pitch through forearm tightness in 2021 may have exacerbated his later issues. Switching to the Rangers involved a long recovery from Tommy John surgery and a new environment. It’s difficult to isolate the contract itself from these confounding events.

Furthermore, age is an undeniable factor. deGrom turned 30 in 2018, the same year he signed his extension. Most pitchers begin to decline in their early 30s, and while deGrom’s performance didn’t decline, his durability did. The combination of age, increased velocity, and higher workload expectations likely created a perfect storm for injuries.

Comparison to Other Big-Contract Pitchers

deGrom’s situation is not unique. Other pitchers who signed massive extensions or free-agent deals often saw similar patterns: Stephen Strasburg signed a $245 million deal with the Nationals in 2019 and made only eight starts afterward due to thoracic outlet syndrome and nerve issues. David Price signed a $217 million deal with the Red Sox and produced three solid seasons before declining. Justin Verlander, however, signed a two-year, $66 million deal with the Astros at age 34 and won two Cy Youngs while remaining healthy. The difference may lie in mechanics, training, or luck.

“deGrom’s case is unique because his per-inning dominance has actually improved with each contract, while his availability has plummeted,” said MLB analyst Eno Sarris. “He’s like a sports car that can hit 200 mph but needs a rebuild every 5,000 miles.”

These comparisons highlight that no single factor determines contract success. The Rangers’ $185 million gamble on deGrom is not yet a bust, but it’s certainly a high-risk investment with limited returns so far.

Did the Contracts Change deGrom?

Yes and no. The talent never wavered—deGrom’s performance after signing both the Mets extension and the Rangers deal was, when he took the mound, even better than before. His 1.08 ERA in 2021 and his 0.69 ERA in four 2024 innings are Hall-of-Fame caliber. The money didn’t arm him with new pitches or fix his command; it simply rewarded what he already was.

But the contracts coincided with a dramatic drop in durability. Whether the cause is age, the pressure to throw harder, the toll of elite performance, or simple bad luck, deGrom has missed more than 60 percent of possible starts since 2020. The ESPN injury timeline documents a cascade of elbow, forearm, shoulder, and side issues that began shortly after his first big payday.

Ultimately, the contracts allowed deGrom to secure generational wealth and remain in the spotlight. They did not alter his competitive drive or his performance ceiling. What they did change was the narrative: a pitcher who once seemed indestructible became a marvel of quality over quantity. For the Mets and Rangers, the gamble was that peak deGrom, even in limited doses, was worth the investment. The data supports both sides of that bet.

Looking Ahead: 2025 and Beyond

As of early 2025, deGrom is attempting another comeback with Texas, still armed with an elite fastball and an unmatched slider. The question is no longer whether he can dominate—he has proven that post-contract—but whether his body can allow him to do so for a full season. The Rangers are cautiously optimistic, limiting his spring training workload and planning for six-inning starts. If he can throw 120–140 innings in 2025, it would be his highest total since 2019.

The answer to the durability question may define his legacy more than any contract ever could. If deGrom manages to stay healthy and deliver a dominant full season, he will be remembered as one of the greatest pitchers of all time. If not, his career will be a cautionary tale about the fragility of excellence. Either way, the numbers show that Jacob deGrom never stopped being elite. He just stopped being available.